Literature DB >> 6285775

Decay of colostral antibodies to bovine leukemia virus with application to detection of calfhood infection.

M C Thurmond, R L Carter, D M Puhr, M J Burridge.   

Abstract

An estimated weighted-regression method was used to describe the decay of colostral bovine leukemia virus (BLV) antibodies in the calf, as measured by agar-gel immunodiffusion with glycoprotein antigen. The prediction equation, based on 473 observations from 130 animals, was log10 inverse titer = 1.29 -0.012 age (days). The half-life of BLV antibodies was estimated to be 25.8 days. Ages at which colostral antibodies were last detected were between 51 and 187 days. Normal limits of antibody decay were estimated and used to identify virus-induced active antibodies in calves during the colostral antibody period. Calves known to be infected were identified between 2 and 180 days of age, using 95% limits. Application of this procedure for the early serologic detection of BLV-infected calves in eradication or control programs is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285775

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  3 in total

1.  Control of bovine leukosis virus in a dairy herd by a change in dehorning.

Authors:  R F DiGiacomo; S G Hopkins; R L Darlington; J F Evermann
Journal:  Can J Vet Res       Date:  1987-10       Impact factor: 1.310

2.  An epidemiological study of natural in utero infection with bovine leukemia virus.

Authors:  M C Thurmond; R L Carter; D M Puhr; M J Burridge; J M Miller; M J Schmerr; M J Van der Maaten
Journal:  Can J Comp Med       Date:  1983-07

Review 3.  Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.

Authors:  Sabrina M Rodríguez; Arnaud Florins; Nicolas Gillet; Alix de Brogniez; María Teresa Sánchez-Alcaraz; Mathieu Boxus; Fanny Boulanger; Gerónimo Gutiérrez; Karina Trono; Irene Alvarez; Lucas Vagnoni; Luc Willems
Journal:  Viruses       Date:  2011-07-19       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.